Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31246024 | 0.94 | BRD4 (0.46) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824785 | 0.91 | BRD4 (0.52) | BRD4GPR119 | |
| SCHEMBL30824873 | 0.91 | BRD4 (0.49) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824864 | 0.91 | BRD4 (0.49) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824779 | 0.90 | BRD4 (0.51) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824809 | 0.90 | BRD4 (0.48) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824812 | 0.90 | BRD4 (0.48) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824887 | 0.87 | BRD4 (0.47) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824837 | 0.87 | BRD4 (0.46) | BRD4GPR119HTR6MEN1KMT2A | |
| SCHEMBL30824848 | 0.87 | BRD4 (0.46) | BRD4GPR119HTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CBR1 | BRD4 260/4885GPR119 1811/4885HTR6 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.